study_id,author,first_dose_only,location_id,location_id2,location_name,location_name2,vac_before_booster,vaccine_developer,variant,symptom_severity,severity,sample_size,age_start,age_end,efficacy_mean,efficacy_lower,efficacy_upper,booster,vemt,mean_time_since_vaccination,start_interval,end_interval,sev_severity,mid_point1,mid_point,group_analysis,study_id2,e_mean,se,mean_logit,sd_logit,in_var
567,Natarajan K,0,102,102,United States,US Omicron,"",Johnson & Johnson,Omicron,severe,hosp,,18,85,0.67,0.52,0.77,0,1,8,,,severe,,8,Omicron,567&US Omicron&Omicron&hosp&18&85,0.57,0.0637755102040816,0.281851152140988,0.260202000016653,0.395979797464467
